進行後の抗EGFR耐性クローンは指数関数的に減衰する：抗EGFR再挑戦の意義

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.2018 · 16 citations
2. 2Emergence of Multiple <i>EGFR</i> Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer2015 · 276 citations
3. 3Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients2015 · 1,096 citations
4. 4Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer2016 · 211 citations
5. 5Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer2017 · 98 citations